Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients.

Abstract

BACKGROUND:

There have been limited studies directly comparing the long-term efficacy between entecavir (ETV) and tenofovir disoproxil fumarate (TDF). This study was aimed to compare the long-term efficacy between them in treatment-naïve chronic hepatitis B (CHB).

METHODS:

Out of 345 CHB patients who received first line therapy with ETV (n = 200) or TDF (n = 145) in a cohort, 210 patients were analyzed using propensity score matching, at a ratio of 1:1.

RESULTS:

Two groups showed no difference in baseline characteristics. During the follow-up of 12 months, HBV DNA levels were similarly suppressed in both groups (ETV vs. TDF; -5.01 vs. -5.242 log10IU/mL, P = 0.559). At month 12, both groups showed no difference in terms of the serologic, biochemical and virologic (VR) response. In multivariate analysis, the initial virologic response at 3 months (IVR-3) was independent factor for VR at 1 year. During the long-term follow-up, HBV DNA levels were more strongly suppressed by TDF than ETV in hepatitis B e antigen (HBeAg) positive patients (P = 0.035), especially with high viral load (P = 0.012), although there was no significant difference in overall VR between two groups. The type of antivirals was not an independent factor for long-term VR.

CONCLUSIONS:

Although either ETV or TDF, overall, may show a comparable long-term antiviral efficacy in treatment-naïve CHB, TDF might be better regimen than ETV in the subgroup of HBeAg-positive CHB, especially with a higher HBV DNA levels.

• Authors: Ji Won Park, Kyeong Min Kwak, Sung Eun Kim, Myoung Kuk Jang, Ki Tae Suk, Dong Joon Kim, Sang Hoon Park, Myung Seok Lee, Hyoung Su Kim, Choong Kee Park
• Journal: BMC gastroenterology (BMC Gastroenterol) Vol. 17 Issue 1 Pg. 39 (Mar 09 2017) ISSN: 1471-230X [Electronic] England
• PMID: 28279168 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antiviral Agents
• DNA, Viral
• entecavir
• Guanine
• Tenofovir

Topics

• Adult
• Antiviral Agents (therapeutic use)
• DNA, Viral (blood, drug effects)
• Female
• Guanine (analogs & derivatives, therapeutic use)
• Hepatitis B virus (drug effects, genetics)
• Hepatitis B, Chronic (drug therapy, virology)
• Humans
• Male
• Middle Aged
• Multivariate Analysis
• Propensity Score
• Tenofovir (therapeutic use)
• Treatment Outcome
• Viral Load (drug effects)